- Home
- HQI vs PBYI Comparison
HQI vs PBYI Comparison
Compare HQI & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQI
- PBYI
- Stock Information
- Founded
- HQI 2002
- PBYI 2010
- Country
- HQI United States
- PBYI United States
- Employees
- HQI N/A
- PBYI N/A
- Industry
- HQI Professional Services
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- HQI Consumer Discretionary
- PBYI Health Care
- Exchange
- HQI Nasdaq
- PBYI Nasdaq
- Market Cap
- HQI 172.8M
- PBYI 176.1M
- IPO Year
- HQI N/A
- PBYI N/A
- Fundamental
- Price
- HQI $14.17
- PBYI $2.50
- Analyst Decision
- HQI Strong Buy
- PBYI Strong Buy
- Analyst Count
- HQI 2
- PBYI 1
- Target Price
- HQI $18.00
- PBYI $7.00
- AVG Volume (30 Days)
- HQI 15.1K
- PBYI 330.8K
- Earning Date
- HQI 11-06-2024
- PBYI 10-31-2024
- Dividend Yield
- HQI 1.71%
- PBYI N/A
- EPS Growth
- HQI N/A
- PBYI N/A
- EPS
- HQI 0.37
- PBYI 0.18
- Revenue
- HQI $36,133,000.00
- PBYI $219,143,000.00
- Revenue This Year
- HQI N/A
- PBYI N/A
- Revenue Next Year
- HQI $7.62
- PBYI N/A
- P/E Ratio
- HQI $33.48
- PBYI $13.95
- Revenue Growth
- HQI 3.96
- PBYI N/A
- 52 Week Low
- HQI $11.39
- PBYI $2.13
- 52 Week High
- HQI $17.31
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- HQI 54.14
- PBYI 42.87
- Support Level
- HQI $13.81
- PBYI $2.45
- Resistance Level
- HQI $14.79
- PBYI $2.63
- Average True Range (ATR)
- HQI 0.52
- PBYI 0.14
- MACD
- HQI -0.01
- PBYI 0.06
- Stochastic Oscillator
- HQI 53.38
- PBYI 65.85
About HQI HireQuest Inc. (DE)
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The primary source of revenue for the company is royalty fees based on the operation of its franchised offices.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.